favezelimab,pembrolizumab
merck,i-mab
['dlbcl', 'favezelimab', 'mk-4280', 'nhl', 'pembro', 'imab ']
favezelimab + pembro r-r chl. phase 2. pd1 failed, about half last line, about half not. orr 29% but most did have a reduction in volume. med pfs 10.7mo did keep some stable lft abn &amp; irrs
some activity but appears modest. not clear what the lag3 adding. #ash22 
Associate Professor of Haematology and lymphoma specialist at Oxford Cancer and Haematology centre. Christian, husband and father.